Use of peptides

Details Use of peptides Use of peptides

2006-11-28

2006-11-28

Weber, Jon (Department: 1653)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C530S300000

Reexamination Certificate

active

07141541

ABSTRACT:
We claim a therapeutic method of inducing programmed cell death comprising administering to a recipient a peptide of 10–25 amino acids, comprising the sequence: (KR)xxYxxx(F/Q)L(L/M) wherein x is any amino acid.

REFERENCES:
patent: 6610508 (2003-08-01), Hentze et al.
patent: WO 94/18345 (1994-08-01), None
patent: WO 96/13614 (1996-05-01), None
patent: WO 98/39357 (1998-09-01), None
Haghighat et al. (1996) The elF4G-elF4E complex is the target for direct cleavage by the rhinovirus 2A proteinase, J. Virol. vol. 70, No. 12, pp. 8444-8450.
De Benedetti, et al., “Overexpression of eukaryotic protein synthesis initiation factor 4E in HeLa cells results in aberrant growth and morphology,”Proc. Natl. Acad. Sci. USA87: 8212-8216 (Nov. 1990).
Dostie, et al., “Nuclear Eukaryotic Initiation Factor 4E (elF4E) Colocalizes with Splicing Factors in Speckles,”The Journal of Cell Biology148(2): 239-245 (2000).
Fletcher, et al., “4E Binding Proteins Inhibit the Translation Factor eIF4E without Folded Structure,”Biochemistry37: 9-15 (1998).
Flynn, et al., “Insulin-stimulated phosphorylation of initiation factor 4E is mediated by the MAP kinase pathway,”Federation of European Biochemical Societies389: 162-166 (1996).
Fukuchi-Shimogori, et al., “Malignant Transformation by Overproduction of Translation Initiation Factor eIF4G,”Cancer Research57: 5041-5044 (1997).
Green, et al., “Mitochondria and Apoptosis,”Science281: 1309-1312 (1998).
Hentze, Matthias W., “elF4G: A Multipurpose Ribosome Adapter?”Science, 275(Jan.): 500-501 (1997).
Kroemer, Guido, “The proto-oncogene Bcl-2 and its role in regulating apoptosis,”Nature Medicine3(6): 614-620 (1997).
Li, et al., “Clinical Outcome in Stage I to III Breast Carcinoma and elF4E Overexpression,”Annals of Surgery227(5): 756-763 (1998).
Li, et al., “Overexpression of Eukaryotic Initiation Factor 4E (elF4E) in Breast Carcinoma,”American Cancer Society79: 2384-2390 (1997).
Minamikawa, et al., “Mitochondrial Permeability Transition and Swelling Can Occur Reversibly without Inducing Cell Death in Intact Human Cells,”Experimental Cell Research246: 26-37 (1999).
O Nathan, et al., “Detection of the proto-oncogene elF4E in surgical margins may predict recurrence in head and neck cancer,”Oncogene15: 579-584 (1997).
Okuno, et al., “Bcl-2 Prevents Caspase-independent Cell Death,”The Journal of Biological Chemistry273(51): 34272-34277.
Pyronnet, et al., “Human eukaryotic translation initiation factor 4G (elF4G) recruits Mnkl to phosphorylate elF4E,”EMBO Journal, 18(1): 270-279 (1999).
Rosenwald, et al., “Elevated Levels of Cyclin D1 Protein in Response to Increased Expression of Eukaryotic Initiation Factor 4E,”Molecular and Cellular Biology Dec.: 7358-7363 (1993).
Rosenwald, et al., “Upregulation of protein synthesis initiation factor eIF-4E is an early event during colon carcinogenesis,”Oncogene18: 2507-2517 (1999).
Rousseau, et al., “The elF4E-binding proteins 1 and 2 are negative regulators of cell growth,”Oncogene13: 2415-2420 (1996).
Shantz, et al., “Regulation of Ornithine Decarboxylase in a Transformed Cell Line That Overexpresses Translation Initiation Factor eIF-4E,”Cancer Research56: 3265-3269 (1996).
Sonenberg, et al., “The mRNA5' cap-binding protein elF4E and control of cell growth,”Current Opinion in Cell Biology, 10: 268-275 (1998).
Sonenberg, et al., “Translational control of apoptosis: An essential role for initiation factor 4E in preventing oncogene-dependent cell death,”Biology 28abstract (1997).
Susin, et al., “Molecular characterization of mitochondrial apoptosis-inducing factor,”Nature397: 441-446 (1999).
Wolf, et al., “Suicidal Tendencies: Apoptotic Cell Death by Caspase Family Preteinases,”The Journal of Biological Chemistry274(29): 20049-20052 (1999).
Xiang, et al., “BAX-induced cell death may not require interleukin 1β-converting enzyme-like proteases,”Proc. Natl. Acad. Sci. USA93: 14559-14563 (1996).
Polunovsky et al. Abstract. “Translational Control of Apoptosis: An Essential Rold for Initiation Factor 4E in Preventing Oncogene-Dependent Cell Death,”Proceedings of the American Association For Cancer Research Annual.1997, vol. 38, pp. 624.
Altmann et al. “A novel inhibitor of cap-dependent translation initiation in yeast: p. 20 competes with eIF4G for binding to eIF4E,”Embo Journal.1997, vol. 16, No. 5, pp. 1114-1121.
Lawrence, J.C. et al. “PHAS/4E-BPs as regulators of mRNA translation and cell proliferation.”Tibs Trends in Biochemical Science.1997, vol. 22, No. 9, pp. 345-349.
Renschler et al. “B-Lymphoma Cells Are Activated by Peptide Ligands of the Antigen Binding Receptor or by Anti-Idiotypic Antibody to Induce Extracellular Acidification,”Cancer Research.Dec. 1, 1995, vol. 55, pp. 5642-5647.

Affiliated with

Also associated with

Rating

Use of peptides does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Use of peptides, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of peptides will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3629507